Search Results - "Bernabé, R."

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial by Soo, R.A., Han, J.-Y., Dafni, U., Cho, B.C., Yeo, C.M., Nadal, E., Carcereny, E., de Castro, J., Sala, M.A., Bernabé, R., Coate, L., Provencio Pulla, M., Garcia Campelo, R., Cuffe, S., Hashemi, S.M.S., Früh, M., Massuti, B., Garcia-Sanchez, J., Dómine, M., Majem, M., Sanchez-Torres, J.-M., Britschgi, C., Pless, M., Dimopoulou, G., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R.A., Peters, S., Stahel, Rolf, Peters, Solange, Soo, Ross, Han, Ji-Youn, Früh, Martin, Provencio, Mariano, Coate, Linda, Dafni, Urania, Hiltbrunner, Anita, Ruepp, Barbara, Roschitzki-Voser, Heidi, Gasca-Ruchti, Adriana, Giacomelli, Nino, Kammler, Rosita, Marti, Nesa, Nobs, Lionel, Pardo-Contreras, Mariana, Pfister, Rita, Piguet, Anne-Christine, Ribeli-Hofmann, Sabrina, Martinez, Virginia Rodriguez, Roux, Susanne, Sanchez-Hohl, Magdalena, Schneider, Mirjam, Schweri, Robin, Troesch, Sandra, Zigomo, Isabel, Tsourti, Zoi, Zygoura, Panagiota, Kassapian, Marie, Vervita, Katerina, Dimopoulou, Georgia, Andriakopoulou, Charitini, Fernandez, Maria, Pereira, Eva, Simona, Carolina, Tucker, Lisa, Burnes, Jillian, Barrett, Aisling, McGrillen, Meghan, Berset, Catherine, Biaggi, Christine, Reist, Martin, Rentsch, Priska, Cuffe, Sinead, Hashemi, Sayed, Nadal, Ernest, Carcereny, Enric, de Castro, Javier, Sala, Maria Angeles, Reyes, Bernabé, Pulla, Mariano Provencio, Campelo, Rosario Garcia, Massutí, Bartomeu, Garcia, Jose, Dómine, Manuel, Majem, Margarita, Sanchez, Jose Miguel, Britschgi, Christian, Pless, Miklos, Yeo, Chong Ming, Cho, Byoung Chul

“…While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with…”
Get full text

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping by Zugazagoitia, J., Ramos, I., Trigo, J.M., Palka, M., Gómez-Rueda, A., Jantus-Lewintre, E., Camps, C., Isla, D., Iranzo, P., Ponce-Aix, S., García-Campelo, R., Provencio, M., Franco, F., Bernabé, R., Juan-Vidal, O., Felip, E., de Castro, J., Sanchez-Torres, J.M., Faul, I., Lanman, R.B., Garrido, P., Paz-Ares, L.

“…Approximately 30% of tumor biopsies from patients with advanced-stage lung adenocarcinomas yield insufficient tissue for successful molecular subtyping. We…”
Get full text

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015 by García-Campelo, R., Bernabé, R., Cobo, M., Corral, J., Coves, J., Dómine, M., Nadal, E., Rodriguez-Abreu, D., Viñolas, N., Massuti, B.

“…Lung cancer is the most common cancer worldwide as well as the leading cause of cancer related deaths as reported by Torre et al (CA Cancer J Clin 65:87–108,…”
Get full text

SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021) by Remon, J., Bernabé, R., Diz, P., Felip, E., González-Larriba, J. L., Lázaro, M., Mielgo-Rubio, X., Sánchez, A., Sullivan, I., Massutti, B.

“…Thymic epithelial tumours (TET) represent a heterogeneous group of rare malignancies that include thymomas and thymic carcinoma. Treatment of TET is based on…”
Get full text

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis by Dafni, U., Soo, R.A., Peters, S., Tsourti, Z., Zygoura, P., Vervita, K., Han, J.-Y., De Castro, J., Coate, L., Früh, M., Hashemi, S.M.S., Nadal, E., Carcereny, E., Sala, M.A., Bernabé, R., Provencio, M., Cuffe, S., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R.A.

“…The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for adding bevacizumab to osimertinib in second line. An…”
Get full text

Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial by Camerini, A., Morabito, A., Montanino, A., Bernabé, R., Grossi, F., Ramlau, R., Ciuleanu, T.-E., Ceresoli, G.-L., Pasello, G., de Marinis, F., Bosch-Barrera, J., Laundreau, P., Gautier, S., Ta Thanh Minh, C., Kowalski, D.

“…To assess the efficacy and safety of a metronomic schedule of oral vinorelbine (mVNR) in advanced non-small-cell lung cancer (NSCLC) in patients unfit for…”
Get full text

ID 322 – Familial Creutzfeldt-Jakob disease. All night v-polysomnography study by Maeztu, C, López-Bernabé, R, Candel, J, Salmerón, P, Gómez, C

“…Introduction The familial form of Creutzfeldt-Jakob disease (fCJD) is a dominantly inherited prion disease caused by mutations in the prion protein gene. We…”
Get full text

ID 347 – Facial myokymia in devic disease by Maeztu, M.C, Villaverde, R, Moreno, J, Cuadrado, J, Lopez-Bernabé, R, Garcia, Luis

“…Introduction Neuromyelitis optica, also known as Devic disease,is one of the inflammatory idiopathic demyelinating diseases of the central nervous system…”
Get full text

Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment by Herrero Rivera, D., Nieto-Guerrero Gómez, J. M., Cacicedo Fernández de Bobadilla, J., Delgado, D., Rivin del Campo, E., Praena-Fernández, J. M., Bernabé Caro, R., Ortiz Gordillo, M. J., Fernández Fernández, M. C., Lopez Guerra, J. L.

“…Purpose Chronic inflammation contributes to cancer development via multiple mechanisms. We hypothesized that cardiovascular diseases (CVD) are also an…”
Get full text

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies by MORAN, T, WEI, J, CHAIB, I, YOU, C, MASSUTI, B, SONG, Y, VERGNENEGRE, A, LU, H, LOPEZ-VIVANCO, G, HU, W, ROBINET, G, YAN, J, COBO, M, INSA, A, XU, X, MAJEM, M, CHEN, X, DE LAS PENAS, R, KARACHALIOU, N, SALA, M. A, WU, Q, ISLA, D, ZHOU, Y, QIAN, X, BAIZE, N, ZHANG, F, GARDE, J, GERMONPRE, P, RAUH, S, ALHUSAINI, H, SANCHEZ-RONCO, M, DROZDOWSKYJ, A, SANCHEZ, J. J, CAMPS, C, DOMINE, M, LIU, B, ROSELL, R, ZOU, Z, BOVER, I, WANG, L, PROVENCIO, M, YU, L

“…In a Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein 80 (RAP80) expression was significantly…”
Get full text

Bus, minibus, metro inter-comparison of commuters’ exposure to air pollution in Mexico City by Gómez-Perales, J.E., Colvile, R.N., Fernández-Bremauntz, A.A., Gutiérrez-Avedoy, V., Páramo-Figueroa, V.H., Blanco-Jiménez, S., Bueno-López, E., Bernabé-Cabanillas, R., Mandujano, F., Hidalgo-Navarro, M., Nieuwenhuijsen, M.J.

“…Commuters’ exposure measurements were taken for PM 2.5, carbon monoxide (CO) and benzene in minibuses, buses and metro during morning and evening rush hours…”
Get full text

Sodium oxybate and modafinil: A good combination? by Ortega-Albás, J.J, López-Bernabé, R, Serrano, A.L, Díaz, J.R

Get full text

Status dissociatus: la expresión más extrema de los estados de disociación by Miró-Andreu, A., López-Bernabé, R., Garnés Sánchez, M.C., Maeztu Sardiña, M.C.

Get full text

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial by Remon, J., Besse, B., Aix, S. Ponce, Callejo, A., Al-Rabi, K., Bernabe, R., Greillier, L., Majem, M., Reguart, N., Monnet, I., Cousin, S., Garrido, P., Robinet, G., Garcia Campelo, R., Madroszyk, A., Mazières, J., Curcio, H., Wasąg, B., Pretzenbacher, Y., Fournier, B., Dingemans, A.-M.C., Dziadziuszko, R.

“…The APPLE trial aimed to evaluate the feasibility of longitudinal plasma epidermal growth factor receptor (EGFR) T790M monitoring for the best sequencing…”
Get full text

Hallazgos electroencefalográficos y polisomnográficos en un paciente con enfermedad de Creutzfeldt-Jakob familiar by Garnés Sánchez, C.M, López Bernabé, R, Miró-Andreu, A, Maeztu Sardiña, M.C, Salmerón-Ato, P

Get full text

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis by Borghaei, H., Ciuleanu, T.-E., Lee, J.-S., Pluzanski, A., Caro, R. Bernabe, Gutierrez, M., Ohe, Y., Nishio, M., Goldman, J., Ready, N., Spigel, D.R., Ramalingam, S.S., Paz-Ares, L.G., Gainor, J.F., Ahmed, S., Reck, M., Maio, M., O’Byrne, K.J., Memaj, A., Nathan, F., Tran, P., Hellmann, M.D., Brahmer, J.R.

“…First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC). We further characterized clinical…”
Get full text

Comparative immunohistochemical study of normal, hyperplastic and neoplastic C cells of the rat thyroid gland by Martín-Lacave, I, Rojas, F, Bernabé, R, Utrilla, J C, Fernández-Santos, J M, De Miguel, M, Conde, E

“…In rats, the frequency of spontaneous C-cell tumours is very high and is both age and gender dependent. The three specific stages of neoplastic progression can…”
Get full text

Ethics in clinical trial regulation: ethically relevant issues from EMA inspection reports by Bernabe, R. D. L. C., van Thiel, G. J. M. W., Breekveldt, N. S., Gispen-de Wied, C. C., van Delden, J. J. M.

“…Background: Within the EU, regulators are obliged to take ethical issues into consideration during marketing authorization deliberation. The goal of this…”
Get full text

PM speciation and sources in Mexico during the MILAGRO-2006 Campaign by Querol, X., Pey, J., Minguillón, M. C., Pérez, N., Alastuey, A., Viana, M., Moreno, T., Bernabé, R. M., Blanco, S., Cárdenas, B., Vega, E., Sosa, G., Escalona, S., Ruiz, H., Artíñano, B.

“…Levels of PM10, PM2.5 and PM1 and chemical speciation of PM10 and PM2.5 were measured during the MILAGRO campaign (1st to 31st March 2006, but extended in some…”
Get full text

Vertical distribution of ozone and VOCs in the low boundary layer of Mexico City by Velasco, E., Márquez, C., Bueno, E., Bernabé, R. M., Sánchez, A., Fentanes, O., Wöhrnschimmel, H., Cárdenas, B., Kamilla, A., Wakamatsu, S., Molina, L. T.

“…The evolution of ozone (O3) and 13 volatile organic compounds (VOCs) in the boundary layer of Mexico City was investigated during 2000–2004 to improve our…”
Get full text